• Omnigel strengthens its portfolio with the introduction of Omnigel Maxstrong

    Omnigel strengthens its portfolio with the introduction of Omnigel Maxstrong

    The new variant is built for individuals whose active routines often lead to repeated muscle and joint discomfort Marks its entry into the 2% diclofenac category to address recurring pain with long-lasting relief MUMBAI, India, July 6, 2026 /PRNewswire/ — Omnigel, Cipla Health’s leading pain relief brand, has announced the launch of Omnigel Maxstrong, its…

    Continue Reading

  • Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business

    Acquisition supports Servier’s strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion. SURESNES, France, June 1, 2026 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, today announced that…

    Continue Reading